1. Anticoagulant users warned of food and herbal interactions

   News item 20 April 2024 Pages: 1 - 1

2. Aruba Aloe products recalled due to presence of methanol

   Media release 20 April 2024 Pages: 2 - 2

3. Atovaquone oral suspension USP 750 mg/5mL: recall due to microbial contamination

   Media release 20 April 2024 Pages: 3 - 3

4. Flucloxacillin-related oesophageal disorders

   News item 20 April 2024 Pages: 4 - 4

5. PRAC meeting highlights April 2024

   News item 20 April 2024 Pages: 5 - 5

6. Radiation recall reaction triggered by chemotherapy

   News item 20 April 2024 Pages: 6 - 6

7. Tejocote root products recalled due to toxic oleander

   News item 20 April 2024 Pages: 7 - 7

8. Conventional and biological DMARD-related ADRs

   Clinical study 20 April 2024 Pages: 8 - 8

9. COVID-19 vaccine-related heavy menstrual bleeding

   Clinical study 20 April 2024 Pages: 9 - 9

10. GLP1 receptor agonists do not increase risk of thyroid cancer

    Clinical study 20 April 2024 Pages: 10 - 10

11. Methotrexate may reduce risk of dementia

    Clinical study 20 April 2024 Pages: 11 - 11

12. Prenatal cannabis use increases risk of ADHD and autism in children

    Clinical study 20 April 2024 Pages: 12 - 12

13. Other adverse reaction research

    News item 20 April 2024 Pages: 13 - 13

14. Anaesthetics

    Case report 20 April 2024 Pages: 14 - 14

15. Acetylcysteine/paracetamol

    Case report 20 April 2024 Pages: 15 - 15

16. Aciclovir/Loxoprofen/Valaciclovir

    Case report 20 April 2024 Pages: 16 - 16

17. Acitretin/mycophenolate-mofetil/prednisone

    Case report 20 April 2024 Pages: 17 - 17

18. Adalimumab/azathioprine

    Case report 20 April 2024 Pages: 18 - 18

19. Adalimumab/methylprednisolone/minocycline

    Case report 20 April 2024 Pages: 19 - 19

20. Adenosine/Verapamil

    Case report 20 April 2024 Pages: 20 - 20

21. Adenosine/verapamil

    Case report 20 April 2024 Pages: 21 - 21

22. Alendronic-acid

    Case report 20 April 2024 Pages: 22 - 22

23. Alendronic-acid

    Case report 20 April 2024 Pages: 23 - 23

24. Alogliptin

    Case report 20 April 2024 Pages: 24 - 24

25. Alpelisib

    Case report 20 April 2024 Pages: 25 - 25

26. Alteplase

    Case report 20 April 2024 Pages: 26 - 26

27. Alteplase

    Case report 20 April 2024 Pages: 27 - 27

28. Alteplase/heparin

    Case report 20 April 2024 Pages: 28 - 28

29. Amantadine

    Case report 20 April 2024 Pages: 29 - 29

30. Amikacin/carboplatin

    Case report 20 April 2024 Pages: 30 - 30

31. Amikacin/Enbucrilate/Penicillamine

    Case report 20 April 2024 Pages: 31 - 31

32. Amiodarone

    Case report 20 April 2024 Pages: 32 - 32

33. Amiodarone

    Case report 20 April 2024 Pages: 33 - 33

34. Amiodarone

    Case report 20 April 2024 Pages: 34 - 34

35. Amiodarone/apixaban

    Case report 20 April 2024 Pages: 35 - 35

36. Amiodarone/Lidocaine

    Case report 20 April 2024 Pages: 36 - 36

37. Amiodarone/lidocaine/sotalol

    Case report 20 April 2024 Pages: 37 - 37

38. Amlodipine

    Case report 20 April 2024 Pages: 38 - 38

39. Amoxicillin/clavulanic-acid/Tetanus-vaccine

    Case report 20 April 2024 Pages: 39 - 39

40. Amphotericin-B-liposomal/flucytosine

    Case report 20 April 2024 Pages: 40 - 40

41. Amphotericin-B/Posaconazole

    Case report 20 April 2024 Pages: 41 - 41

42. Ampicillin/sulbactam

    Case report 20 April 2024 Pages: 42 - 42

43. Amrubicin/pegfilgrastim

    Case report 20 April 2024 Pages: 43 - 43

44. Angiogenesis-inhibitors/pyrotinib

    Case report 20 April 2024 Pages: 44 - 44

45. Antiarrhythmics

    Case report 20 April 2024 Pages: 45 - 45

46. Antibacterials

    Case report 20 April 2024 Pages: 46 - 46

47. Antibacterials

    Case report 20 April 2024 Pages: 47 - 47

48. Antibacterials/prednisone

    Case report 20 April 2024 Pages: 48 - 48

49. Antihypoglycaemics/hydrocortisone/octreotide

    Case report 20 April 2024 Pages: 49 - 49

50. Antineoplastics

    Case report 20 April 2024 Pages: 50 - 50